The man with a hospital in his hand
Walk into most clinics and an ultrasound is a wheeled cart, a tangle of cables, and a price tag that buys a small house. Amin Nikoozadeh looked at that machine and asked the unglamorous question: why does it have to be big, and why does it have to be expensive?
Nikoozadeh runs Vave Health, a San Jose company that makes a wireless handheld ultrasound probe. It pairs to a phone or tablet. One probe handles shallow scans and deep scans. There is no subscription. That last detail sounds like a footnote until you remember the industry it sits inside, where recurring fees are the business model and the hardware is the hook.
The product is small enough to forget you are carrying it. The ambition is not. Vave's stated mission is to make ultrasound "limitless" by expanding access to reliable imaging for clinicians and communities. That word, access, is the whole company. It is why the device is cheap, rugged, and built to work in a rural clinic as readily as a teaching hospital.
As many as two-thirds of the world's population lack access to medical imaging.
From the catheter tip outward
The origin is not a garage. It is a laboratory bench at Stanford. Nikoozadeh first met ultrasound as a graduate student in the E. L. Ginzton Laboratory, the lab where the discipline of medical ultrasonics has deep roots. His project was a feat of shrinking: fit an entire imaging system onto the tip of a catheter just 3 millimeters across, small enough to thread inside a beating heart.
That work earned him a PhD in electrical engineering, completed in 2010 after years spent on transducer design and the unforgiving physics of making sound waves into pictures. As a senior research engineer he kept going, on catheter-based intracardiac imaging, real-time volumetric ultrasound, and adjacent frontiers in focused-ultrasound and photoacoustic work. Miniaturization was not a buzzword for him. It was a decade of practice.
His research range was wider than a single device. Across his years at the Ginzton Lab he worked on high-intensity focused ultrasound for therapy, low-intensity ultrasound aimed at neurostimulation, and photoacoustic imaging, which marries light and sound to see what neither can alone. The throughline was a refusal to treat ultrasound as a finished technology. To him it was raw physics with a lot of headroom left, and capacitive micromachined transducers were the lever for pulling that headroom out.
Here is the turn. The skill that let him cram an imaging system into a catheter is the same skill that lets you cram one into a pocket. The catheter project was about reaching a place no one could otherwise see. Vave is about reaching people no one else was serving. Same engineering, different target.
We're poised for a year of explosive growth.
The unsexy part: getting cleared
A clever device is a demo. A cleared device is a company. In July 2019 the Vave Personal Ultrasound System received FDA 510(k) clearance, K191541, the regulatory milestone that turns a research-grade idea into a tool a clinician can actually point at a patient. Nikoozadeh has been candid that the year after clearance was spent not chasing headlines but optimizing the product for real manufacturing volume. Hardware does not scale on enthusiasm.
By the company's own count, devices built on Vave's technology have now run more than 10 million scans. The probe shows up where it was designed to be useful: emergency and primary care, rural and underserved settings, and a growing footprint in medical education, where students learn to scan on a device that costs a fraction of the cart in the next room.
The company he built around it
Vave Health is venture-backed but not venture-loud. Crunchbase pegs the company's funding at roughly $6.4 million, with institutional backers including Cota Capital, RONA Holdings, and NAIMIgroup. That is a modest figure for medical hardware, and it tracks with how Nikoozadeh has run the place: deliberate, capital-efficient, and allergic to spending ahead of the engineering. The product line itself is small on purpose. A universal probe for general use across shallow and deep structures, and a phased probe tuned for the deeper work of cardiac, pulmonary, and abdominal imaging. Two tools, not twenty.
As the company matured it pulled in operators who had scaled this exact category before. In early 2025 Vave brought on David Garner, a former vice president at Butterfly Network with more than two decades in the field, as Chief Commercial Officer, and added Terri Bresenham, a former Chief Innovation Officer at GE Healthcare with thirty-plus years in the industry, to its advisory board. Hiring people who have already run the playbook elsewhere is a quiet signal that the founder knows the difference between inventing a device and selling one.
The mission shows up in the partnerships, too. Vave has teamed with the Inteleos Foundation to widen global access to ultrasound, and its devices have moved into medical education at institutions like Touro University California, where students learn to scan on hardware that does not require a hospital's budget. The company says clinicians at Stanford, the University of Arizona, OHSU, and Brigham and Women's Hospital have put the probe to work. For a company whose entire thesis is access, the customer list is the argument.
Engineering as a value system
There is a tell in how Vave describes its own work. It talks about transducers, image processing, machine learning, and cloud computing as a single ecosystem rather than a feature list. That is a founder who thinks in systems, because that is how he was trained. The universal probe with auto-adjust imaging, the cloud storage for sharing exams, the DICOM integration for slotting into hospital workflows, the deliberate refusal to charge a subscription, these are not marketing decisions dressed as engineering. They are engineering decisions that happen to also be a worldview.
Nikoozadeh is not a loud founder. He is the kind who lets the device argue for itself, who spent years on the physics before he ever spent a day on a pitch deck. In a category crowded with sleek consumer-tech energy, his bet is quieter and harder: that the most radical thing you can do with medical imaging is make it boring, cheap, and everywhere.
What he is building toward
The aspiration has not drifted from that first observation about the two-thirds. If imaging is a basic clinical sense, then most of the planet is practicing medicine half-blind. Vave's wager is that the fix is not a fancier hospital. It is a probe cheap and durable enough to put in a backpack, a clinic, a medical school, a place the cart was never going to reach. Nikoozadeh built the technology to thread a heart. Now he is using it to widen a door.